EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient-Derived Organoids in Clinical Medicine: Proven Impact and Future Directions

Magdalena Skowronska, Ece Yildiz, Jens Grosch, Mairene Coto-Llerena

Organoids · 21.05.2026 · 5 (2) · 15

DOI: 10.3390/organoids5020015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Organoids, online erschienen am 21.05.2026. Verfasst von Magdalena Skowronska und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patient-derived organoids (PDOs) have rapidly transitioned from research tools into promising platforms for clinical translation. In this review, we analyze 139 PDO-related clinical trials registered between 2023 and 2025 and contrast them with recent advances in disease modelling. Our analysis revealed a predominance of oncology-focused studies, with translational maturity spanning from foundational research to studies in which PDOs directly informed clinical decision-making. In contrast, non-oncology areas show extensive preclinical progress but remain trial-poor. We found that trial registration is geographically concentrated in a small number of countries, reflecting uneven global adoption. We then explored advances in disease modeling, mainly confined to preclinical studies, including immune-competent PDOs, complex organ-on-a-chip systems, synthetic matrices, AI-enabled platforms, and therapeutic transplantation. Based on these findings, we propose a conceptual framework outlining the trajectory of PDO adoption in clinical trials. This trajectory can be understood as three overlapping waves of translation: the first wave, focusing on oncology, has already demonstrated impacts on patient care; the second, targeting non-oncology diseases, is scientifically advanced but has not achieved widespread clinical application; and the third, involving frontier technologies, remains in the preclinical stage. Understanding these trajectories underscores the promise and challenges of PDOs that must be addressed for broader clinical adoption.

Zitieren

APA

Skowronska, M., Yildiz, E., Grosch, J., & Coto-Llerena, M. (2026). Patient-Derived Organoids in Clinical Medicine: Proven Impact and Future Directions. Organoids, 5(2), 15. https://doi.org/10.3390/organoids5020015

Vancouver

Skowronska M, Yildiz E, Grosch J, Coto-Llerena M. Patient-Derived Organoids in Clinical Medicine: Proven Impact and Future Directions. Organoids. 2026;5(2):15. doi:10.3390/organoids5020015

BibTeX
@article{Skowronska2026,
  author = {Skowronska, Magdalena and Yildiz, Ece and Grosch, Jens and Coto-Llerena, Mairene},
  title = {Patient-Derived Organoids in Clinical Medicine: Proven Impact and Future Directions},
  journal = {Organoids},
  year = {2026},
  volume = {5},
  number = {2},
  pages = {15},
  doi = {10.3390/organoids5020015}
}
Kostenlos starten →